Clinical Trials
11 trialsNCT07525869 2026-04-20
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
Yonsei University
Phase NA Recruiting
NCT05296317 2026-02-19
EMEG-ECDD
Centre Georges Francois Leclerc
Phase NA Completed
NCT01850888 2025-12-18
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT05834751 2023-04-28
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
The First Hospital of Jilin University
Phase NA Unknown
NCT00346125 2022-12-15
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00283621 2018-11-07
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
M.D. Anderson Cancer Center
Phase NA Completed
NCT00689884 2018-04-20
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Phase NA Terminated
NCT00615901 2017-03-03
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01541072 2016-11-01
PALM2
Centre Leon Berard
Phase NA Terminated
NCT00436709 2014-01-06
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
National Cancer Institute (NCI)
Phase NA Unknown
NCT00310089 2013-06-20
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase NA Completed